The firm aims to integrate protein biomarker measurements, data from patient wearables, and imaging to improve treatment and management of multiple sclerosis.
In studies of 140 multiple sclerosis patients and controls, the researchers identified two blood-based metabolites as potential markers of the disease.
The firm's recent funding round will support its CLIA-certified laboratory that opened last year and the launch of its first RNA-based diagnostic test.
A Winthrop-University Hospital team showed that demethylated circulating cell-free DNA from dying oligodendrocytes is a biomarker for relapsing-remitting MS.
